Clinical Trials · NCT06855589
Optimal Duration of Hormonal Therapy for Unfavorable Intermediate-risk Prostate Cancer Patients: 6 Versus 12 Months.
- Phase
- Phase 3
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Charles LeMoyne Hospital
- Enrollment
- 400
- Start date
- Mar 2025
- Locations
- 5 sites, Canada
- Primary endpoint
- biochemical progression-free survival